Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This phase 2 clinical trial will evaluate the effectiveness and safety of fludarabine in
combination with CPX-351 in patients with untreated AML. Patients will receive fludarabine
and CPX-351 during Induction 1 and 2 as well as 2 cycles of consolidation therapy.